Drug intelligence / Profile preview

OT-Combination

Development stage: Preclinical
Lead developer: Pangea Bio

Overview

**OT-Combination** is a preclinical Pangea Bio therapeutic combination program reported to target the tropomyosin receptor kinase B pathway for melanoma and neurodegeneration. Publicly available information does not identify the individual active substances, formulation, route of administration, or the precise pharmacologic effect at the TrkB receptor. Pangea Bio's currently available public materials describe its broader TrkB-focused central nervous system pipeline but do not substantiate an exact program named OT-Combination.

Targets

NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on OT-Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OT-Combination.

Explore the full profile